Inhalation devices: from basic science to practical use, innovative vs generic products

Expert Opinion on Drug Delivery

Volumn 13, Issue 11, 2016, Pages 1559-1571

  Pirozynski, Michal ^a   Sosnowski, Tomasz R ^b  

^a Dept of Neurology and Epileptology Med Ctr for Postgraduate Education   (Poland)

^b WARSAW UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

aerosol; bioequivalence; Drug administration; drug approval; drug delivery systems; generic drugs; inhalation; inhalers; lung deposition; nebulizers and vaporizers

Indexed keywords

GENERIC DRUG; AEROSOL;

AEROSOL; DRUG EFFICACY; DRUG USE; DRY POWDER INHALER; EXPERIMENTAL THERAPY; HUMAN; INHALER; METERED DOSE INHALER; NEBULIZER; RESPIRATORY SYSTEM; REVIEW; ADMINISTRATION AND DOSAGE; COMPARATIVE STUDY; INHALATIONAL DRUG ADMINISTRATION;

ADMINISTRATION, INHALATION; AEROSOLS; HUMANS; NEBULIZERS AND VAPORIZERS;

EID: 84991292397     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1080/17425247.2016.1198774     Document Type: Review

References (93)

1. R.U.Agu, M.I.Ugwoke, M.Armand, et al. The lung as a route for systemic delivery of therapeutic proteins and peptides. Respir Res. 2001;2:198–209.
2. S.J.Farr, B.A.Otulana Pulmonary delivery of opioids as pain therapeutics. Adv Drug Deliv Rev. 2006;58:1076–1088.
3. T.B.Martonen, Z.Zhang, G.Yue, et al. Fine particle deposition within human nasal airways. Inhal Toxicol. 2003;15:283–303.
4. J.Marijnissen, L.Gradon Nanoparticles in medicine and environment. Inhalation and health effects. Dordrecht:Springer; 2010.•• A comprehensive book covering physical and biological aspects of microparticle and nanoparticle inhalation.
5. USP. Aerosols, nasal sprays, metered dose inhalers and dry powder inhalers. Rockville:US Pharmacopeial Convention; 2008.
6. European pharmacopeia. 8th ed. Strasburg:European Directorate for the Quality of Medicines and Healthcare; 2013.
7. L.Borgstrom, B.Olsson, L.Thorsson Degree of throat deposition can explain the variability in lung deposition of inhaled drugs. J Aerosol Med. 2006;19:473–483.
8. M.Hussain, W.-H.Renate, H.Werner. Effect of intersubject variability of extrathoracic morphometry, lung airways dimensions and respiratory parameters on particle deposition. J Thorac Dis. 2011;3:156–170.
9. H.Adi, P.M.Young, D.Traini. Co-deposition of a triple therapy drug formulation for the treatment of chronic obstructive pulmonary disease using solution-based pressurised metered dose inhalers. J Pharm Pharmacol. 2012;64:1245–1253.
10. S.P.Newman, W.W.Busse. Evolution of dry powder inhaler design, formulation, and performance. Respir Med. 2002;96:293–304.
11. A.Moskal, L.Gradon. Temporary and spatial deposition of aerosol particles in the upper human airways during breathing cycle. J Aerosol Sci. 2002;33:1525–1539.
12. T.R.Sosnowski, A.Moskal, L.Gradon. Dynamics of oropharyngeal aerosol transport and deposition with the realistic flow pattern. Inhal Toxicol. 2006;18:773–780.• Article demonstrates the importance of flow dynamics during inspiration for aerosol deposition in the UA.
13. F.E.Fresconi, A.K.Prasad. Secondary velocity fields in the conducting airways of the human lung. J Biomech Eng. 2007;129:722–732.
14. A.Moskal, T.R.Sosnowski. Dynamics of aerosol pulse in a simplified mouth. Throat geometry and its significance for inhalation drug delivery. Chem Proc Eng. 2009;30:545–558.
15. Z.Zhang, C.Kleinstreuer. Transient airflow structures and particle transport in a sequentially branching lung airway model. Phys Fluids. 2002;14:862–880.
16. R.M.DiBlasi. Clinical controversies in aerosol therapy for infants and children. Respir Care. 2015;60:894-914; discussion 14-16.•• Comprehensive review of the challenges in aerosol therapy in the youngest patients.
17. P.H.Howarth. Why particle size should affect clinical response to inhaled therapy. J Aerosol Med. 2001;14(Suppl 1):S27-S34.
18. M.Van Den Berge, N.H.Ten Hacken, E.Van Der Wiel, et al. Treatment of the bronchial tree from beginning to end:targeting small airway inflammation in asthma. Allergy. 2013;68:16–26.
19. W.D.Bennett, J.S.Brown, K.L.Zeman, et al. Targeting delivery of aerosols to different lung regions. J Aerosol Med. 2002;15:179–188.
20. K.L.Zeman, J.Wu, W.D.Bennett. Targeting aerosolized drugs to the conducting airways using very large particles and extremely slow inhalations. J Aerosol Med Pulm Drug Deliv. 2010;23:363–369.
21. E.R.Weibel. Morphometry of the human lung. Berlin:Springer; 1963.
22. W.M.van Aalderen, L.Garcia-Marcos, M.Gappa, et al. How to match the optimal currently available inhaler device to an individual child with asthma or recurrent wheeze. NPJ Prim Care Respir Med. 2015;25:14088.
23. K.Svartengren, P.Lindestad, M.Svartengren, et al. Added external resistance reduces oropharyngeal deposition and increases lung deposition of aerosol particles in asthmatics. Am J Respir Crit Care Med. 1995;152:32–37.
24. A.B.Montgomery. Status of aerosolized pentamidine for treatment and of Pneumocystiscarinii pneumonia. J Aerosol Med. 1989;2:233–238.
25. S.P.Newman, K.P.Steed, S.J.Reader, et al. Efficient delivery to the lungs of flunisolide aerosol from a new portable hand-held multidose nebulizer. J Pharm Sci. 1996;85:960–964.
26. D.Hochrainer, H.Holz, C.Kreher, et al. Comparison of the aerosol velocity and spray duration of Respimat Soft Mist inhaler and pressurized metered dose inhalers. J Aerosol Med. 2005;18:273–282.
27. K.Simis, M.Lei, A.T.Lu, et al. Nicotine aerosol generation from thermally reversible zinc halide complexes using the Staccato system. Drug Dev Ind Pharm. 2008;34:936–942.
28. L.Y.Yeo, J.R.Friend, M.P.McIntosh, et al. Ultrasonic nebulization platforms for pulmonary drug delivery. Expert Opin Drug Deliv. 2010;7:663–679.
29. A.R.Martin, W.H.Finlay. Nebulizers for drug delivery to the lungs. Expert Opin Drug Deliv. 2015;12:889–900.•• Summary of nebulization technology.
30. R.E.Van Dyke, K.Nikander. Delivery of iloprost inhalation solution with the HaloLite, Prodose, and I-neb Adaptive Aerosol Delivery systems:an in vitro study. Respir Care. 2007;52:184–190.
31. J.Denyer, T.Dyche. The Adaptive Aerosol Delivery (AAD) technology:past, present, and future. J Aerosol Med Pulm Drug Deliv. 2010;23(Suppl 1):S1-S10.
32. R.Dhand. Intelligent nebulizers in the age of the Internet:the I-neb Adaptive Aerosol Delivery (AAD) system. J Aerosol Med Pulm Drug Deliv. 2010;23(Suppl 1):iii–v.
33. J.Mazela, K.Chmura, M.Kulza, et al. Aerosolized albuterol sulfate delivery under neonatal ventilatory conditions:in vitro evaluation of a novel ventilator circuit patient interface connector. J Aerosol Med Pulm Drug Deliv. 2014;27:58–65.
34. Y.S.Cheng, C.S.Fu, D.Yazzie, et al. Respiratory deposition patterns of salbutamol pMDI with CFC and HFA-134a formulations in a human airway replica. J Aerosol Med. 2001;14:255–266.
35. W.Wilkes, J.Fink, R.Dhand. Selecting an accessory device with a metered-dose inhaler:variable influence of accessory devices on fine particle dose, throat deposition, and drug delivery with asynchronous actuation from a metered-dose inhaler. J Aerosol Med. 2001;14:351–360.
36. S.Erzinger, K.G.Schueepp, J.Brooks-Wildhaber, et al. Facemasks and aerosol delivery in vivo. J Aerosol Med. 2007;20(Suppl 1):S78-S83; discussion S83-S84.
37. V.Giraud, N.Roche. Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability. Eur Respir J. 2002;19:246–251.
38. S.P.Newman. Principles of metered-dose inhaler design. Respir Care. 2005;50:1177–1190.• Summary of pMDI technology.
39. S.W.Stein, P.Sheth, P.D.Hodson, et al. Advances in metered dose inhaler technology:hardware development. AAPS PharmSciTech. 2014;15:326–338.• Article discusses novel ideas in use of pMDIs.
40. S.P.Newman, A.W.Weisz, N.Talaee, et al. Improvement of drug delivery with a breath actuated pressurised aerosol for patients with poor inhaler technique. Thorax. 1991;46:712–716.
41. V.Jones, C.Fernandez, P.Diggory. A comparison of large volume spacer, breath-activated and dry powder inhalers in older people. Age Ageing. 1999;28:481–484.
42. S.G.Devadason, T.Huang, S.Walker, et al. Distribution of technetium-99m-labelled QVAR delivered using an Autohaler device in children. Eur Respir J. 2003;21:1007–1011.
43. R.Vehring, D.Lechuga-Ballesteros, V.Joshi, et al. Cosuspensions of microcrystals and engineered microparticles for uniform and efficient delivery of respiratory therapeutics from pressurized metered dose inhalers. Langmuir. 2012;28:15015–15023.
44. N.Islam, E.Gladki. Dry powder inhalers (DPIs) – a review of device reliability and innovation. Int J Pharm. 2008;360:1–11.•• Summary of DPI technology.
45. G.W.Canonica, J.Arp, J.R.Keegstra, et al. Spiromax, a new dry powder inhaler:dose consistency under simulated real-world conditions. J Aerosol Med Pulm Drug Deliv. 2015;28:309–319.
46. N.J.Harper, S.Gray, J.De Groot, et al. The design and performance of the exubera pulmonary insulin delivery system. Diabetes Technol Ther. 2007;9(Suppl 1):S16-S27.
47. H.Nelson, J.P.Kemp, S.Bieler, et al. Comparative efficacy and safety of albuterol sulfate Spiros inhaler and albuterol metered-dose inhaler in asthma. Chest. 1999;115:329–335.
48. M.Hoppentocht, P.Hagedoorn, H.W.Frijlink, et al. Technological and practical challenges of dry powder inhalers and formulations. Adv Drug Deliv Rev. 2014;75:18–31.•• Summary of DPI technology.
49. B.Olsson, L.Asking. Critical aspects of the function of inspiratory flow driven inhalers. J Aerosol Med. 1994;7(Suppl 1):S43-S47.
50. P.Kruger, B.Ehrlein, M.Zier, et al. Inspiratory flow resistance of marketed dry powder inhalers (DPI). Eur Respir J. 2014;44(Suppl 58):4635.
51. B.Olsson. Aerosol particle generation from dry powder inhalers:can they equal pressurized metered dose inhalers? J Aerosol Med. 1995;8(Suppl 3):S13-S18; discussion S19.
52. J.Gac, T.R.Sosnowski, L.Gradon. Turbulent flow energy for aerosolization of powder particles. J Aerosol Sci. 2008;3:113–126.
53. H.Chrystyn, D.Price. Not all asthma inhalers are the same:factors to consider when prescribing an inhaler. Prim Care Respir J. 2009;18:243–249.
54. P.Demoly, P.Hagedoorn, A.H.de Boer, et al. The clinical relevance of dry powder inhaler performance for drug delivery. Respir Med. 2014;108:1195–1203.
55. X.M.Zeng, G.P.Martin, C.Marriott, et al. Lactose as a carrier in dry powder formulations:the influence of surface characteristics on drug delivery. J Pharm Sci. 2001;90:1424–1434.
56. G.Pilcer, K.Amighi. Formulation strategy and use of excipients in pulmonary drug delivery. Int J Pharm. 2010;392:1–19.
57. Y.Rahimpour, H.Hamishehkar. Lactose engineering for better performance in dry powder inhalers. Adv Pharm Bull. 2012;2:183–187.
58. L.Gradon, T.R.Sosnowski. Formation of particles for dry powder inhalers. Adv Powder Technol. 2014;25:43–55.• Article discusses selected aspects of powder engineering problems in DPIs.
59. A.H.Chow, H.H.Tong, P.Chattopadhyay, et al. Particle engineering for pulmonary drug delivery. Pharm Res. 2007;24:411–437.•• Summary of powder engineering issues for pulmonary applications.
60. K.G.Nielsen, M.Skov, B.Klug, et al. Flow-dependent effect of formoterol dry-powder inhaled from the Aerolizer. Eur Respir J. 1997;10:2105–2109.
61. T.Weuthen, S.Roeder, P.Brand, et al. In vitro testing of two formoterol dry powder inhalers at different flow rates. J Aerosol Med. 2002;15:297–303.
62. H.Chrystyn. The Diskus:a review of its position among dry powder inhaler devices. Int J Clin Pract. 2007;61:1022–1036.
63. K.Wetterlin. Turbuhaler:a new powder inhaler for administration of drugs to the airways. Pharm Res. 1988;5:506–508.
64. L.Borgstrom, L.Asking, L.Thorsson. Idealhalers or realhalers? A comparison of Diskus and Turbuhaler. Int J Clin Pract. 2005;59:1488–1495.
65. S.Chodosh, J.S.Flanders, S.Kesten, et al. Effective delivery of particles with the HandiHaler dry powder inhalation system over a range of chronic obstructive pulmonary disease severity. J Aerosol Med. 2001;14:309–315.
66. M.A.Siddiqui, G.L.Plosker. The Novolizer:a multidose dry powder inhaler. Treat Respir Med. 2005;4:63–69.
67. M.Corradi, H.Chrystyn, B.G.Cosio, et al. NEXThaler, an innovative dry powder inhaler delivering an extrafine fixed combination of beclometasone and formoterol to treat large and small airways in asthma. Expert Opin Drug Deliv. 2014;11:1497–1506.
68. H.Svedsater, P.Dale, K.Garrill, et al. Qualitative assessment of attributes and ease of use of the ELLIPTA dry powder inhaler for delivery of maintenance therapy for asthma and COPD. BMC Pulm Med. 2013;13:72.
69. W.Azouz, P.Chetcuti, H.S.Hosker, et al. The inhalation characteristics of patients when they use different dry powder inhalers. J Aerosol Med Pulm Drug Deliv. 2015;28:35–42.•• Review of the effect of different inhalation profiles in patents using DPIs.
70. D.Lu, S.L.Lee, R.A.Lionberger, et al. International guidelines for bioequivalence of locally acting orally inhaled drug products:similarities and differences. AAPS J. 2015;17:546–557.
71. CHMP. Guideline on the pharmaceutical quality of inhalation and nasal products. London:EMA; 2005.
72. S.L.Lee, B.Saluja, A.Garcia-Arieta, et al. Regulatory considerations for approval of generic inhalation drug products in the US, EU, Brazil, China, and India. AAPS J. 2015;17:1285–1304.
73. J.J.Borg, A.Tanti, D.Kouvelas, et al. European Union pharmacovigilance capabilities:potential for the new legislation. Ther Adv Drug Saf. 2015;6:120–140.
74. A.Moskal, T.R.Sosnowski. Computational fluid dynamics (CFD) and direct visualization studies of aerosol release from two cyclohaler-type dry powder inhalers. J Drug Deliv Sci Technol. 2012;22:161–165.
75. CHMP. Guideline on the requirements for clinical documentation for orally inhaled products (OIP) including the requirements for demonstration of therapeutic equivalence between two inhaled products for use in the treatment of asthma and chronic obstructive pulmonary disease (COPD) in adults and for use in the treatment of asthma in children and adolescents. London:EMA; 2009.
76. G.Apiou-Sbirlea, S.Newman, J.Fleming, et al. Bioequivalence of inhaled drugs:fundamentals, challenges and perspectives. Ther Deliv. 2013;4:343–367.
77. B.L.Laube, H.M.Janssens, F.H.De Jongh, et al. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J. 2011;37:1308–1331.
78. A.Ari, R.D.Restrepo. American association for respiratory care. Aerosol delivery device selection for spontaneously breathing patients:2012. Respir Care. 2012;57:613–626.
79. M.L.Everard. Inhalation therapy for infants. Adv Drug Deliv Rev. 2003;55:869–878.
80. M.L.Everard. Inhaler devices in infants and children:challenges and solutions. J Aerosol Med. 2004;17:186–195.
81. G.E.Taffet, J.F.Donohue, P.R.Altman. Considerations for managing chronic obstructive pulmonary disease in the elderly. Clin Interv Aging. 2014;9:23–30.
82. A.Ari, A.D.de Andrade, M.Sheard, et al. Performance comparisons of jet and mesh nebulizers using different interfaces in simulated spontaneously breathing adults and children. J Aerosol Med Pulm Drug Deliv. 2015;28:281–289.
83. C.Darquenne, J.S.Fleming, I.Katz, et al. Bridging the gap between science and clinical efficacy:physiology, imaging, and modeling of aerosols in the lung. J Aerosol Med Pulm Drug Deliv. 2016;29:107–126.
84. D.A.Mahler, L.A.Waterman, J.Ward, et al. Comparison of dry powder versus nebulized beta-agonist in patients with COPD who have suboptimal peak inspiratory flow rate. J Aerosol Med Pulm Drug Deliv. 2014;27:103–109.
85. GOLD Global Strategy for the diagnosis, management and prevention of COPD. 2016. [cited 2016 Apr12]. Available from:www.goldcopd.org
86. P.J.Atkins. Dry powder inhalers:an overview. Respir Care. 2005;50:1304-1312; discussion 12.
87. R.A.Al-Showair, W.Y.Tarsin, K.H.Assi, et al. Can all patients with COPD use the correct inhalation flow with all inhalers and does training help? Respir Med. 2007;101:2395–2401.
88. S.Jarvis, P.W.Ind, R.J.Shiner. Inhaled therapy in elderly COPD patients; time for re-evaluation? Age Ageing. 2007;36:213–218.
89. D.A.Mahler, L.A.Waterman, A.H.Gifford. Prevalence and COPD phenotype for a suboptimal peak inspiratory flow rate against the simulated resistance of the Diskus® dry powder inhaler. J Aerosol Med Pulm Drug Deliv. 2013;26:174–179.
90. L.Gradon, T.Sosnowski, W.Ruminski, et al. Inhaler for powder drug administration. EP2157990B1. Munich:European Patent Bulletin 2014/31; 2014.
91. F.Lavorini, F.Braido, I.Baiardini, et al. Asthma and COPD:interchangeable use of inhalers. A document of Italian Society of Allergy, Asthma and Clinical Immmunology (SIAAIC) & Italian Society of Respiratory Medicine (SIMeR). Pulm Pharmacol Ther. 2015;34:25–30.
92. A.E.Williams, H.Chrystyn. Survey of pharmacists’ attitudes towards interchangeable use of dry powder inhalers. Pharm World Sci. 2007;29:221–227.
93. J.J.Borg, G.Aislaitner, M.Pirozynski, et al. Strengthening and rationalising pharmacovigilance in the European Union. Where is Europe heading to? A review of the new EU legislation on pharmacovigilance. Drug Saf. 2011;34:187–197.